# Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

> **NCT04214418** · PHASE1,PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 27 (actual)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Hydroxychloroquine
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04214418
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-12
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-07-01
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Toxicity and Lack of Efficacy
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04214418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04214418, "Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04214418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*